International Congress

Forum Life Science 2015

11/12 March 2015, Technische Universität München - Garching

Pharma Development

 
Pharma Development
 
Wednesday, 11 March 2015
 
Strategies and Trends in Pharma Development

Chair: Prof. Dr. Horst Domdey
CEO, BioM Cluster Development GmbH, Martinsried

14:00 - 14:25
Novel tools for novel medicines – Precise genome editing and stem cell technologies

Dr. Lorenz M. Mayr
Vice President & Global Head, Reagents & Assay Development, AstraZeneca, Macclesfield, United Kingdom

14:25 - 14:50
Research and partnering strategy at Bayer Pharma

Dr. Matthias Gottwald
Global Drug Discovery, Global External Innovation and Alliances, Bayer Pharma AG, Berlin

14:50 - 15:15
Indications and targets for new antibody based therapies

Dr. Ralf Schumacher
Head of Large Molecule Research, Roche, Penzberg

15:15 - 15:30
Discussions
15:30 - 16:00
Coffee break in the exhibition
 
Immuno-Oncology and intervention

Chair: Dr. Christian Reiser
Project Manager Life Science, Bayern Innovativ GmbH, Nuremberg

16:00 - 16:25
Chimeric Antigen Receptor (CAR) T cell therapy: CTL019 and beyond

Dr. Andreas Löw
Head New Technologies, Novartis Institutes for Biomedical Research Inc, NIBR Biologics Center, Cambridge, USA

16:25 - 16:50
Selective activation of the extrinsic apoptosis pathway by the bispecific FAP-DR5 antibody

Dr. Klaus Bosslet
Head Discovery Oncology, Roche, Penzberg

16:50 - 17:15
From TGN1412 to TAB08 – Lessons from the past and new clinical developments

Prof. Dr. Thomas Hünig
Institute for Virology and Immunobiology, University of Würzburg

17:15 - 18:00
Elevator Pitches
  • RealTVac® - eine neuartige Strategie in der Immunotherapie maligner Tumore mittels einer Echtzeit-Tumorvakzine
    Dr. Piotr Jachimczak, RealTVac, Würzburg
  • 3D cell culture models for testing biologicals
    Dr. Jens Kelm, InSphero AG, Schlieren (CH)
from 19:00
Reception at Dachau Palace

Franz Josef Pschierer
State Secretary, Bavarian Ministry of Economic Affairs and Media, Energy and Technology

 
Thursday, 12 March 2015
 
Cell-based Therapies and Technologies

Chair: Prof. Dr. Klaus Überla
Department of Clinical and Molecular Virology, Friedrich-Alexander Universität Erlangen-Nürnberg

09:15 - 09:40
Central role of DCs in immune therapy

Dr. Marnix Bosch
CTO, Northwest Biotherapeutics GmbH, Leipzig

09:40 - 10:05
Harnessing the power of T cells for treatment of cancer

Prof. Dr. Dolores J. Schendel
Managing Director, Medigene Immunotherapies GmbH, Martinsried/Munich

10:05 - 10:30
ONE Study – A unified approach to evaluating cellular immunotherapy in solid organ transplantation

Prof. Edward K. Geissler, PhD
Head of Experimental Surgery, University Hospital Regensburg

10:30 - 10:55
Next generation cell therapy

Dr. Volker Scherhammer
Leiter Klinische Entwicklung, apceth GmbH & Co. KG, Munich

10:55 - 11:20
AdiVaSc – Application of adipose-derived stem cells to produce a vascularized adipose transplant

Prof. Dr. Heike Walles
Department Tissue Engineering und Regenerative Medicine (TERM), University Hospital Wuerzburg and Translational Center Wuerzburg ´Regenerative therapies`
Prof. Dr. Torsten Blunk
Klinik und Poliklinik für Unfall-, Hand-, Plastische und Wiederherstellungschirurgie Universitätsklinikum Wuerzburg

11:20 - 11:45
Elevator Pitches
  • Potential of human induced pluripotent stem cells (ForIPS)
    Dr. Jürgen Winkler, M.D., Professor of Neurology, Universitätsklinikum Erlangen, FAU Erlangen-Nürnberg
  • Visualization, counting and sizing of Extracellular Vesicles by Nanoparticle Tracking Analysis (NTA)
    Dr. Clemens HelmbrechtParticle Metrix GmbH, Dießen
  • Photons on duty for health - Label-free Monitoring of drug-induced cell reaction
    Dr. Karin Schütze, CellTool GmbH, Bernried
  • Discover beyond vision - Cell imaging with Venneos
    Jonas Lehmann, Venneos GmbH, Stuttgart
11:45 - 13:30
Lunch break in the exhibition
 
Infectious Diseases

Chair: Prof. Dr. Ralf Wagner
Institute of Medical Microbiology and Hygiene, University of Regensburg

13:30 - 13:55
Recombinant vaccinia virus MVA for rapid vaccine development against West Nile fever, MERS and Ebola

Dr. Asisa Volz
Institute for Infectious Diseases and Zoonoses, Department of Virology, Ludwig-Maximilians-Universität München

13:55 - 14:20
Development of vaccines – A look behind the scenes

Dr. Jens Vollmar
Medical therapeutic area vaccines, tropical and travel medicine, GlaxoSmithKline GmbH & Co. KG, Munich

14:20 - 15:15
Elevator Pitches
  • FORBIMED: An industry/academia research collaboration - Biomarkers in the fight against infectious diseases Prof. Dr. Ralf Wagner, Universität Regensburg
  • Next-Generation diagnostics of infectious diseases Dr. Kai Sohn, Fraunhofer IGB, Stuttgart
  • siPOOLsTM: target-specific RNAi with complex siRNA pools Dr. Michael Hannus, siTOOLs Biotech GmbH, Planegg/Martinsried
15:15 - 15:45
Coffee break in the exhibition
 
DNA-, RNA- and Antisense-based Therapies

Chair: Prof. Dr. Arne Skerra
Biological Chemistry, Technische Universität München, Freising-Weihenstephan

15:45 - 16:10
DNA-based immune therapies against cancer

Dr. Matthias Schroff
CEO, MOLOGEN AG, Berlin

16:10 - 16:35
Protein replacement by transcript therapy

PD Dr. Carsten Rudolph (CEO), Prof. Dr. Christian Plank (CSO)
ethris GmbH, Martinsried/Munich

16:35 - 17:00
Biomarkers in developing molecular and cellular ALS treatment concepts

Prof. Dr. Ulrich Bogdahn
Department of Neurology, University of Regensburg

on March 13th, a workshop on "Predictive Drug De-risking with 3D Cell-based Assays" will take place at the Technische Universität München, Garching.

Further information can be found here: http://www.eventbrite.com/e/insphero-user-group-meeting-munich-registration-15604171497?aff=InSpheroWeb